The drospirenone (DRSP)-only pill: clinical implications in the daily use

Kristina Gemzell‐Danielsson, Ali Kubba, Santiago Palacios, Enrico Colli, Pedro‐Antonio Regidor, Inka Wiegratz, Giovanni Grandi
2023-01-02

SCID:  54.1/zpvhckcx
OBJECTIVES: Progestins used in contraception are either components of combined hormonal contraceptives or are used as a single active ingredient. Progestins are highly effective in long-term contraception and have a very good safety profile with very few contraindications. METHODS: An oestrogen-free ovulation inhibitor POP has been authorised in the USA and the EU. It contains 4 mg of drospirenone (DRSP). The hormone administration regimen of 24 days followed by a 4-day hormone-free period was chosen to improve bleeding control and to maintain oestradiol concentrations at early follicular- phase levels, preventing oestrogen deficiency. RESULTS: Clinical trials have demonstrated high contraceptive effectiveness, a very low risk of cardiovascular risk events and a favourable bleeding pattern. Due to the long half-life of DRSP (30-34 h), the effectiveness is maintained even in case of a forgotten pill on a single occasion. Studies involving deliberate 4 days in one cycle 24-hour delays in taking a pill have demonstrated that ovulation inhibition is maintained if a single pill is missed. CONCLUSIONS: This review article will describe the clinical impact in the daily use of the 4 mg DRSP only pill and the resulting data on the effectiveness and safety of this hormonal contraceptive.
Publication Details
Publication Date
2023-01-02
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Kristina Gemzell‐Danielsson
Ali Kubba
Santiago Palacios
Enrico Colli
Pedro‐Antonio Regidor
Inka Wiegratz
Giovanni Grandi
Explore More Research
Use the citation graph to discover related papers and expand your research horizons.
Click any node to explore
Download PDF
100%